Management of Urinary Tract Infections in the Era of Increasing Antimicrobial Resistance

Medical Clinics of North America

Volumn 97, Issue 4, 2013, Pages 737-757

  Shepherd, Amanda Kay ^a   Pottinger, Paul S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute cystitis; Fosfomycin; Nitrofurantoin; Recurrent UTI; Resistance; Trimethoprim sulfamethoxazole; Urinary tract infection

Indexed keywords

ALDOSTERONE ANTAGONIST; BALSALAZIDE; CHLOROPHACINONE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG ADDITIVE; ESTROGEN; FOSFOMYCIN; LEVOFLOXACIN; METHANAMINE MANDELATE; METHENAMINE; METHENAMINE HIPPURATE; METHOTREXATE; METOCLOPRAMIDE; NITROFURANTOIN; QUINOLONE DERIVATIVE; SPERMICIDAL AGENT; SULFONYLUREA; THEOPHYLLINE; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; BACTERIAL INFECTION; BLEEDING; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONCURRENT SEXUAL PARTNERSHIP; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; CRANBERRY; CYSTOSCOPY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ENTEROBACTERIACEAE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH BEHAVIOR; HEPATITIS; HUMAN; HYPERKALEMIA; INFECTION PREVENTION; LUNG FIBROSIS; NAUSEA; PATHOGENESIS; PATIENT SATISFACTION; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK FACTOR; SEIZURE; SEXUAL INTERCOURSE; SKIN IRRITATION; STEVENS JOHNSON SYNDROME; TENDON RUPTURE; URETHRA DISEASE; URINARY TRACT INFECTION; VAGINITIS; VOMITING;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; INAPPROPRIATE PRESCRIBING; LIFE STYLE; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; URINARY TRACT INFECTIONS;

EID: 84879780307     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.03.006     Document Type: Review

References (102)

1. Schappert S.M., Rechtsteiner E.A. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13 2011, 169:1-38.
2. Foxman B., Barlow R., D'Arcy H., et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000, 10(8):509-515.
3. Foxman B., Frerichs R.R. Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. Am J Public Health 1985, 75(11):1308-1313.
4. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. JAntimicrob Chemother 2003, 51(1):69-76.
5. Khawcharoenporn T., Vasoo S., Ward E., et al. High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012, 30(1):68-74.
6. Kahlmeter G., Poulsen H.O. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents 2012, 39(1):45-51.
7. Gupta K., Hooton T.M., Naber K.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52(5):e103-e120.
8. Johnson L., Sabel A., Burman W.J., et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008, 121(10):876-884.
9. Grover M.L., Bracamonte J.D., Kanodia A.K., et al. Assessing adherence to evidence-based guidelines for the diagnosis and management of uncomplicated urinary tract infection. Mayo Clin Proc 2007, 82(2):181-185.
10. Kallen A.J., Welch H.G., Sirovich B.E. Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med 2006, 166(6):635-639.
11. Tenover F.C. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006, 119(6 Suppl 1):S3-S10. [discussion: S62-70].
12. Opal S., Pop-Vicas A. Molecular mechanisms of antibiotic resistance in bacteria. Mandell, Douglas, and Bennet's principles and practice of infectious disease 2010, vol. 1. Churchill Livingstone Elsevier, Philadelphia. 7th edition.
13. Arnold R.S., Thom K.A., Sharma S., et al. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. Southampt Med J 2011, 104(1):40-45.
14. Gupta N., Limbago B.M., Patel J.B., et al. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011, 53(1):60-67.
15. Naas T., Nordmann P., Vedel G., et al. Plasmid-mediated carbapenem-hydrolyzing -lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrobial Agents Chemother 2005, 49(10):4423-4424.
16. Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients-Rhode Island, March 2012. Available at: Accessed December 27, 2012. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6124a3.htm.
17. Nordmann P., Poirel L., Walsh T.R., et al. The emerging NDM carbapenemases. Trends Microbiol 2011, 19(12):588-595.
18. Wilson M.E., Chen L.H. NDM-1 and the role of travel in its dissemination. Curr Infect Dis Rep 2012, 14(3):213-226.
19. Miller L.G., Tang A.W. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004, 79(8):1048-1053. [quiz: 1053-4].
20. Richards D.A., Toop L.J., Chambers S.T., et al. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. NZ Med J 2002, 115(1146):12-14.
21. Giesen L.G., Cousins G., Dimitrov B.D., et al. Predicting acute uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy of symptoms and signs. BMC Fam Pract 2010, 11:78.
22. Devillé W.L., Yzermans J.C., Van Duijn N.P., et al. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol 2004, 4:4.
23. Little P., Turner S., Rumsby K., et al. Validating the prediction of lower urinary tract infection in primary care: sensitivity and specificity of urinary dipsticks and clinical scores in women. Br J Gen Pract 2010, 60(576):495-500.
24. Kunin C.M., White L.V., Hua T.H. Areassessment of the importance of "low-count" bacteriuria in young women with acute urinary symptoms. Ann Intern Med 1993, 119(6):454-460.
25. Fenwick E.A., Briggs A.H., Hawke C.I. Management of urinary tract infection in general practice: a cost-effectiveness analysis. Br J Gen Pract 2000, 50(457):635-639.
26. Saint S., Scholes D., Fihn S.D., et al. The effectiveness of a clinical practice guideline for the management of presumed uncomplicated urinary tract infection in women. Am J Med 1999, 106(6):636-641.
27. O'Connor P.J., Solberg L.I., Christianson J., et al. Mechanism of action and impact of a cystitis clinical practice guideline on outcomes and costs of care in an HMO. Jt Comm J Qual Improv 1996, 22(10):673-682.
28. Little P., Moore M.V., Turner S., et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ 2010, 340:c199.
29. Vellinga A., Murphy A.W., Hanahoe B., et al. Amultilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. JAntimicrob Chemother 2010, 65(7):1514-1520.
30. Zhanel G.G., Hisanaga T.L., Laing N.M., et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006, 27(6):468-475.
31. Colgan R., Johnson J.R., Kuskowski M., et al. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrobial Agents Chemother 2008, 52(3):846-851.
32. Vellinga A., Tansey S., Hanahoe B., et al. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model. JAntimicrob Chemother 2012, 67(10):2523-2530.
33. Brumfitt W., Hamilton-Miller J.M. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience. JAntimicrob Chemother 1998, 42(3):363-371.
34. MACROBID (nitrofurantoin monohydrate and nitrofurantoin, macrocrystalline) capsule [Procter and Gamble Pharmaceuticals, Inc.]. Daily Med Current Medication Information. Available at: Accessed December 5, 2012. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm%3fsetid%3d1971e893-5fdb-41e3-a1e9-5e52deed03d1.
35. Petri W. Goodman & Gilman's the pharmacological basis of therapeutics 2011, McGraw-Hill, New York. 12th edition.
36. Penn R.G., Griffin J.P. Adverse reactions to nitrofurantoin in the United Kingdom, Sweden, and Holland. Br Med J (Clin Res Ed) 1982, 284(6327):1440-1442.
37. Mendez J.L., Nadrous H.F., Hartman T.E., et al. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc 2005, 80(10):1298-1302.
38. ACOG Committee Opinion No.494 Sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol 2011, 117(6):1484-1485.
39. LactMed. Drugs and lactation database. 2010. Available at: Accessed December 5, 2012. http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f%3f./temp/%7Ev5mwMX:1.
40. Linnebur S.A., Parnes B.L. Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment. Ann Pharmacother 2004, 38(4):612-616.
41. Iravani A., Klimberg I., Briefer C., et al. Atrial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. JAntimicrob Chemother 1999, 43(Suppl A):67-75.
42. Gupta K., Hooton T.M., Roberts P.L., et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007, 167(20):2207-2212.
43. Ho J.M., Juurlink D.N. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 2011, 183(16):1851-1858.
44. Alappan R., Perazella M.A., Buller G.K. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996, 124(3):316-320.
45. Alappan R., Buller G.K., Perazella M.A. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem?. Am J Nephrol 1999, 19(3):389-394.
46. Fischer H.D., Juurlink D.N., Mamdani M.M., et al. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010, 170(7):617-621.
47. Ressel G. AAP updates statement for transfer of drugs and other chemicals into breast milk. American Academy of Pediatrics. Am Fam Physician 2002, 65(5):979-980.
48. Minassian M.A., Lewis D.A., Chattopadhyay D., et al. Acomparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int JAntimicrob Agents 1998, 10(1):39-47.
49. Deck D., Winston L. Beta-Lactam and other cell wall- and membrane-active antibiotics. Basic & clinical pharmacology 2012, McGraw-Hill, New York. 12th edition.
50. Trevor A., Katzunk B., Masters S. Beta-Lactam antibiotics and other cell wall synthesis inhibitors. Pharmacology: examination and board review 2010, McGraw-Hill, New York. 9th edition.
51. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53(4):637-656.
52. Michalopoulos A.S., Livaditis I.G., Gougoutas V. The revival of fosfomycin. Int JInfect Dis 2011, 15(11):e732-e739.
53. Naber K.G. Fosfomycin trometamol in treatment of uncomplicated lower urinary tract infections in adult women-an overview. Infection 1992, 20(Suppl 4):S310-S312.
54. Reeves D.S. Fosfomycin trometamol. JAntimicrob Chemother 1994, 34(6):853-858.
55. Falagas M.E., Kastoris A.C., Kapaskelis A.M., et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10(1):43-50.
56. Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999, 21(11):1864-1872.
57. Henry D.C., Bettis R.B., Riffer E., et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002, 24(12):2088-2104.
58. Van der Linden P.D., Sturkenboom M.C., Herings R.M., et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002, 324(7349):1306-1307.
59. Deck D., Winston L. Sulfonamides, trimethoprim, quinolones. Basic and clinical pharmacology 2012, McGraw-Hill, New York. 12th edition.
60. Hooton T.M., Roberts P.L., Stapleton A.E. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012, 307(6):583-589.
61. Kavatha D., Giamarellou H., Alexiou Z., et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrobial Agents Chemother 2003, 47(3):897-900.
62. Horn J., Hansten P. Drug interactions: absence of proof is not proof of absence. Pharmacy Times 2010, 46.
63. Dickinson B., Altman R., Nielsen N., et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001, 98(5 Pt 1):853-860.
64. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am JPublic Health 1990, 80(3):331-333.
65. Stamm W.E., McKevitt M., Roberts P.L., et al. Natural history of recurrent urinary tract infections in women. Rev Infect Dis 1991, 13(1):77-84.
66. Foxman B., Gillespie B., Koopman J., et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000, 151(12):1194-1205.
67. Scholes D., Hooton T.M., Roberts P.L., et al. Risk factors for recurrent urinary tract infection in young women. JInfect Dis 2000, 182(4):1177-1182.
68. Hooton T.M., Scholes D., Hughes J.P., et al. Aprospective study of risk factors for symptomatic urinary tract infection in young women. NEngl J Med 1996, 335(7):468-474.
69. Fihn S.D., Latham R.H., Roberts P., et al. Association between diaphragm use and urinary tract infection. JAMA 1985, 254(2):240-245.
70. Scholes D., Hawn T.R., Roberts P.L., et al. Family history and risk of recurrent cystitis and pyelonephritis in women. JUrol 2010, 184(2):564-569.
71. Ikäheimo R., Siitonen A., Heiskanen T., et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 1996, 22(1):91-99.
72. Hooton T.M., Stapleton A.E., Roberts P.L., et al. Perineal anatomy and urine-voiding characteristics of young women with and without recurrent urinary tract infections. Clin Infect Dis 1999, 29(6):1600-1601.
73. Sheinfeld J., Schaeffer A.J., Cordon-Cardo C., et al. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. NEngl J Med 1989, 320(12):773-777.
74. Hawn T.R., Scholes D., Li S.S., et al. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS One 2009, 4(6):e5990.
75. Foxman B., Marsh J., Gillespie B., et al. Condom use and first-time urinary tract infection. Epidemiology 1997, 8(6):637-641.
76. Stamatiou C., Bovis C., Panagopoulos P., et al. Sex-induced cystitis-patient burden and other epidemiological features. Clin Exp Obstet Gynecol 2005, 32(3):180-182.
77. McGroarty J.A., Tomeczek L., Pond D.G., et al. Hydrogen peroxide production by Lactobacillus species: correlation with susceptibility to the spermicidal compound nonoxynol-9. JInfect Dis 1992, 165(6):1142-1144.
78. Hooton T.M., Fennell C.L., Clark A.M., et al. Nonoxynol-9: differential antibacterial activity and enhancement of bacterial adherence to vaginal epithelial cells. JInfect Dis 1991, 164(6):1216-1219.
79. Klebanoff S.J. Effects of the spermicidal agent nonoxynol-9 on vaginal microbial flora. JInfect Dis 1992, 165(1):19-25.
80. US Food and Drug Administration. Drug approvals and databases. Available at: Accessed November 9, 2012. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm.
81. Falagas M.E., Betsi G.I., Tokas T., et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs 2006, 66(9):1253-1261.
82. Karlsson M., Scherbak N., Khalaf H., et al. Substances released from probiotic Lactobacillus rhamnosus GR-1 potentiate NF-κB activity in Escherichia coli-stimulated urinary bladder cells. FEMS Immunol Med Microbiol 2012, 66(2):147-156.
83. Gupta K., Stapleton A.E., Hooton T.M., et al. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. JInfect Dis 1998, 178(2):446-450.
84. Barrons R., Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008, 30(3):453-468.
85. Stapleton A.E., Au-Yeung M., Hooton T.M., et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 2011, 52(10):1212-1217.
86. Beerepoot M.A., Ter Riet G., Nys S., et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012, 172(9):704-712.
87. Tempera G., Corsello S., Genovese C., et al. Inhibitory activity of cranberry extract on the bacterial adhesiveness in the urine of women: an ex-vivo study. Int J Immunopathol Pharmacol 2010, 23(2):611-618.
88. Wang C.H., Fang C.C., Chen N.C., et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012, 172(13):988-996.
89. Stapleton A.E., Dziura J., Hooton T.M., et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc 2012, 87(2):143-150.
90. Beerepoot M.A., Ter Riet G., Nys S., et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med 2011, 171(14):1270-1278.
91. Lee B.S., Bhuta T., Simpson J.M., et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev 2012, (10). CD003265.
92. Suckling J., Lethaby A., Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006, (4). CD001500.
93. Pabich W.L., Fihn S.D., Stamm W.E., et al. Prevalence and determinants of vaginal flora alterations in postmenopausal women. JInfect Dis 2003, 188(7):1054-1058.
94. Perrotta C., Aznar M., Mejia R., et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008, (2). CD005131.
95. Engel J.D., Schaeffer A.J. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Urol Clin North Am 1998, 25(4):685-701. x.
96. Johansen T.E. The role of imaging in urinary tract infections. World J Urol 2004, 22(5):392-398.
97. Van Haarst E.P., Van Andel G., Heldeweg E.A., et al. Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology 2001, 57(6):1068-1072.
98. Lawrentschuk N., Ooi J., Pang A., et al. Cystoscopy in women with recurrent urinary tract infection. Int J Urol 2006, 13(4):350-353.
99. Albert X., Huertas I., Pereiró I.I., et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004, (3). CD001209.
100. Stapleton A., Latham R.H., Johnson C., et al. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. JAMA 1990, 264(6):703-706.
101. Melekos M.D., Asbach H.W., Gerharz E., et al. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. JUrol 1997, 157(3):935-939.
102. Zhong Y.H., Fang Y., Zhou J.Z., et al. Effectiveness and safety of patient initiated single-dose versus continuous low-dose antibiotic prophylaxis for recurrent urinary tract infections in postmenopausal women: a randomized controlled study. JInt Med Res 2011, 39(6):2335-2343.